hydroxyurea has been researched along with Myelodysplastic Syndromes in 46 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 9.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "An elderly woman receiving chronic hydroxyurea therapy for myelodysplasia developed a dermatomyositis-like eruption that was misdiagnosed as true dermatomyositis, leading to continuation of hydroxyurea." | 7.76 | Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. ( Burruss, JB; Callen, JP; Cely, SJ; Kalajian, AH; Malone, JC, 2010) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 6.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 5.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "A 62-year-old man with refractory leukemia transformed from myelodysplastic syndrome was placed on hydroxyurea (hydroxycarbamide) at a daily dose of 500 mg." | 4.90 | [Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test]. ( Karigane, D; Kikuchi, T; Koda, Y; Mori, T; Nakajima, H; Okamoto, S; Shimizu, T; Toyama, T, 2014) |
| "An elderly woman receiving chronic hydroxyurea therapy for myelodysplasia developed a dermatomyositis-like eruption that was misdiagnosed as true dermatomyositis, leading to continuation of hydroxyurea." | 3.76 | Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. ( Burruss, JB; Callen, JP; Cely, SJ; Kalajian, AH; Malone, JC, 2010) |
| " In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 3.73 | GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. ( Chan, GW; Miller, KB; Winer, ES, 2005) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | 2.73 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "Myelodysplastic syndrome with chromosomal translocation t(5;12)(q31-33;p12-13) and eosinophilia is a new entity recently described." | 2.39 | Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature. ( Baranger, L; Blanchet, O; François, S; Ifrah, N; Larget-Piet, L; Le Moine, PJ; Pellier, I; Rialland, X, 1996) |
| "Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs." | 1.91 | Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. ( Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Shallis, RM; Stempel, JM; Wang, R; Zeidan, AM, 2023) |
| "Acute myeloid leukemia was finally diagnosed in October 1998, and chromosomal analysis disclosed inv(3) in addition to -5 and -7." | 1.31 | [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. ( Aoki, K; Chiba, S; Hirai, H; Honda, H; Horikoshi, M; Itikawa, M; Kurokawa, M; Machida, U; Masuda, S; Mitani, K; Ogawa, S; Seo, S; Sunaga, S; Yazaki, Y, 2000) |
| "We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS)." | 1.31 | Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. ( Flamm, MJ; Murty, VV; Nichols, GL; Rao, PH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 9 (19.57) | 18.2507 |
| 2000's | 18 (39.13) | 29.6817 |
| 2010's | 16 (34.78) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, R | 1 |
| Shallis, RM | 1 |
| Stempel, JM | 1 |
| Huntington, SF | 1 |
| Zeidan, AM | 1 |
| Gore, SD | 1 |
| Ma, X | 1 |
| Podoltsev, NA | 1 |
| Pan, DQ | 1 |
| Zhao, WS | 1 |
| Yin, CX | 1 |
| He, H | 1 |
| Lin, R | 1 |
| Zhao, K | 1 |
| Ye, JY | 1 |
| Liu, QF | 1 |
| Dai, M | 1 |
| Chang, L | 1 |
| Duan, MH | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 1 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 2 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 2 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 4 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 1 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Minniti, CP | 1 |
| Huemer, F | 1 |
| Weiss, L | 1 |
| Faber, V | 1 |
| Neureiter, D | 1 |
| Egle, A | 1 |
| Geissler, K | 1 |
| Voskova, D | 1 |
| Zebisch, A | 1 |
| Burgstaller, S | 1 |
| Pichler, A | 1 |
| Stauder, R | 1 |
| Sperr, W | 1 |
| Lang, A | 1 |
| Pfeilstöcker, M | 1 |
| Machherndl-Spandl, S | 1 |
| Stampfl, M | 1 |
| Greil, R | 1 |
| Pleyer, L | 1 |
| Wang, HY | 1 |
| Dell'Aquila, ML | 1 |
| Dvanajscak, Z | 1 |
| Bejar, R | 1 |
| Broome, HE | 1 |
| Hsi, E | 1 |
| Murray, SS | 1 |
| Thorson, JA | 1 |
| Ghosh, K | 2 |
| Bain, BJ | 1 |
| Garnett, C | 1 |
| Deplano, S | 1 |
| Naresh, K | 1 |
| Kanfer, E | 1 |
| Shimizu, T | 1 |
| Mori, T | 1 |
| Karigane, D | 1 |
| Kikuchi, T | 1 |
| Koda, Y | 1 |
| Toyama, T | 1 |
| Nakajima, H | 1 |
| Okamoto, S | 1 |
| Itzykson, R | 1 |
| Itzkson, R | 1 |
| Solary, E | 1 |
| Gotlib, J | 1 |
| Crittenden, SC | 1 |
| Gilbert, JE | 1 |
| Callen, JP | 2 |
| Willemze, R | 1 |
| Suciu, S | 1 |
| Muus, P | 1 |
| Halkes, CJ | 1 |
| Meloni, G | 2 |
| Meert, L | 1 |
| Karrasch, M | 1 |
| Rapion, J | 1 |
| Vignetti, M | 1 |
| Amadori, S | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Björkholm, M | 1 |
| Hultcrantz, M | 1 |
| Derolf, ÅR | 1 |
| Aumont, C | 1 |
| Driss, F | 1 |
| Lazure, T | 1 |
| Picard, V | 1 |
| Creidy, R | 1 |
| De Botton, S | 1 |
| Saada, V | 1 |
| Lambotte, O | 1 |
| Bilhou-Nabera, C | 1 |
| Tertian, G | 1 |
| Michot, JM | 1 |
| Sunami, Y | 1 |
| Gotoh, A | 1 |
| Watanabe, N | 1 |
| Edahiro, Y | 1 |
| Hamano, Y | 1 |
| Harada, H | 1 |
| Komatsu, N | 1 |
| Nand, S | 1 |
| Godwin, J | 1 |
| Smith, S | 1 |
| Barton, K | 1 |
| Michaelis, L | 1 |
| Alkan, S | 1 |
| Veerappan, R | 1 |
| Rychlik, K | 1 |
| Germano, E | 1 |
| Stiff, P | 1 |
| Cook-Norris, RH | 1 |
| Mansfield, AS | 1 |
| Michaels, JD | 1 |
| Davis, MD | 1 |
| Kalajian, AH | 1 |
| Cely, SJ | 1 |
| Malone, JC | 1 |
| Burruss, JB | 1 |
| Petti, MC | 1 |
| Tafuri, A | 1 |
| Latagliata, R | 1 |
| Aloe Spiriti, MA | 1 |
| Montefusco, E | 1 |
| Mancini, M | 1 |
| Petrucci, MT | 1 |
| Spadea, A | 1 |
| Redi, R | 1 |
| Alimena, G | 1 |
| Mandelli, F | 1 |
| Spell, DW | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| Lengfelder, E | 1 |
| Berger, U | 1 |
| Reiter, A | 1 |
| Hochhaus, A | 1 |
| Hehlmann, R | 1 |
| Fruchtman, SM | 1 |
| Winer, ES | 1 |
| Miller, KB | 1 |
| Chan, GW | 1 |
| Thiele, J | 1 |
| Kvasnicka, HM | 1 |
| Ollig, S | 1 |
| Schmitt-Gräff, A | 2 |
| Daskalakis, M | 1 |
| Mauritzson, N | 1 |
| Johansson, B | 1 |
| Bouabdallah, K | 1 |
| Onida, F | 1 |
| Kunzmann, R | 1 |
| Müller-Berndorff, H | 1 |
| Lübbert, M | 1 |
| Kiladjian, JJ | 1 |
| Rain, JD | 2 |
| Bernard, JF | 1 |
| Briere, J | 1 |
| Chomienne, C | 1 |
| Gologan, R | 1 |
| Stoia, R | 1 |
| Radulescu, I | 1 |
| Georgescu, D | 1 |
| Ostroveanu, D | 1 |
| Burnett, AK | 1 |
| Milligan, D | 1 |
| Prentice, AG | 1 |
| Goldstone, AH | 1 |
| McMullin, MF | 1 |
| Hills, RK | 1 |
| Wheatley, K | 1 |
| Ostro, D | 1 |
| Cheung, K | 1 |
| Kamel-Reid, S | 1 |
| Lipton, JH | 1 |
| Najean, Y | 1 |
| Toubert, ME | 1 |
| Pellier, I | 1 |
| Le Moine, PJ | 1 |
| Rialland, X | 1 |
| François, S | 1 |
| Baranger, L | 1 |
| Blanchet, O | 1 |
| Larget-Piet, L | 1 |
| Ifrah, N | 1 |
| Pulik, M | 1 |
| Lionnet, F | 1 |
| Genet, P | 1 |
| Petitdidier, C | 1 |
| Jary, L | 1 |
| Touahri, T | 1 |
| Jacob, A | 1 |
| Griffiths, M | 1 |
| Larkins, S | 1 |
| Holmes, J | 1 |
| Sterkers, Y | 1 |
| Preudhomme, C | 1 |
| Laï, JL | 1 |
| Demory, JL | 1 |
| Caulier, MT | 1 |
| Bauters, F | 1 |
| Tefferi, A | 1 |
| Randi, ML | 2 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Horikoshi, M | 1 |
| Machida, U | 1 |
| Itikawa, M | 1 |
| Seo, S | 1 |
| Masuda, S | 1 |
| Kurokawa, M | 1 |
| Ogawa, S | 1 |
| Sunaga, S | 1 |
| Honda, H | 1 |
| Aoki, K | 1 |
| Chiba, S | 1 |
| Mitani, K | 1 |
| Hirai, H | 1 |
| Yazaki, Y | 1 |
| Finazzi, G | 2 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 2 |
| Flamm, MJ | 1 |
| Murty, VV | 1 |
| Rao, PH | 1 |
| Nichols, GL | 1 |
| Advani, SH | 2 |
| Venugopal, P | 1 |
| Charak, BS | 1 |
| Das Gupta, A | 2 |
| Mazumdar, AT | 1 |
| Gopal, R | 2 |
| Nair, CN | 2 |
| Saikia, TK | 2 |
| Nadkarni, KS | 1 |
| Kurkure, PA | 2 |
| van den Anker-Lugtenburg, PJ | 1 |
| Sizoo, W | 1 |
| Giri, NK | 1 |
| Dole, MG | 1 |
| Pai, SK | 1 |
| Pai, VR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Austrian Myeloid Registry[NCT04438889] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2020-07-13 | Recruiting | |||
| A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over[NCT00005823] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than[NCT04687761] | Phase 1/Phase 2 | 84 participants (Anticipated) | Interventional | 2020-11-04 | Recruiting | ||
| The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients[NCT01633099] | Phase 3 | 46 participants (Anticipated) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxyurea and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[Hydroxyurea (hydroxycarbamide)-induced hepatic dysfunction confirmed by drug-induced lymphocyte stimulation test].
Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Fatal Outcome; Humans; Hydroxyurea; I | 2014 |
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Topics: Allografts; Antineoplastic Agents; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, | 2013 |
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Bone Marrow Examination; Clone Cells; Disease Manage | 2014 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature.
Topics: Adult; Child; Chromosome Mapping; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Eosinophi | 1996 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
5 trials available for hydroxyurea and Myelodysplastic Syndromes
33 other studies available for hydroxyurea and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Topics: Aged; Aged, 80 and over; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Medicare; Myelodysplastic Sy | 2023 |
Topics: Adult; Aged; Anemia; Bone Marrow; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myelo | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, | 2018 |
JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia.
Topics: Aged, 80 and over; B7-H1 Antigen; Gene Amplification; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, | 2019 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans | 2013 |
Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum.
Topics: Aged; Antineoplastic Agents; Diagnostic Errors; Female; Humans; Hydroxyurea; Leg Ulcer; Methylenetet | 2014 |
Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Chromosome Aberrations; Chromosomes | 2015 |
[Chronic Myelomonocytic Leukemia with Myelofibrosis Resulting in Sudden Massive Pleural Effusion during Cytoreductive Therapy with Hydroxycarbamide].
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Drainage; Humans; Hydroxyurea; Leukemia, M | 2016 |
Hydroxycarbamide-induced dermopathy.
Topics: Antisickling Agents; Female; Humans; Hydroxyurea; Middle Aged; Myelodysplastic Syndromes; Pruritus | 2010 |
Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure.
Topics: Aged, 80 and over; Dermatomyositis; Diagnosis, Differential; DNA, Neoplasm; Drug Eruptions; Epidermi | 2010 |
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia; Myelodysplastic Syndromes | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[Chronic myeloproliferative diseases. Diagnosis and therapy].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagno | 2003 |
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2005 |
Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Humans; Hydroxyurea; Immunohistochemistry; Me | 2005 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Anal | 2006 |
Chronic myelomonocytic leukemia with overlap dysplastic/proliferative presentation.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chro | 2007 |
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; H | 2007 |
Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.
Topics: Adult; Bone Marrow; Disease Progression; Fatal Outcome; Humans; Hydroxyurea; Leukemia, Monocytic, Ac | 1996 |
t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Chromosome Banding; Chromosomes, Human, Pair 21; Chromosomes, Human, P | 1997 |
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Topics: Adult; Aged; Antisickling Agents; Chromosomes, Human, Pair 17; Female; Gene Deletion; Humans; Hydrox | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair | 2000 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Cell Differentiation; Chronic Disease; Female; Humans; Hy | 2002 |
Effect of hydroxyurea on foetal haemoglobin in myeloproliferative & myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Child; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; My | 1990 |
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb | 1990 |
Limitations of the therapeutic regimens for myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; | 1989 |